Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	30.28	21.59	0	-29.13	-60
Depreciation & Amortization	11.52	11.52	9.84	11.31	10.03
Asset Writedown & Restructuring Costs	-	0.63	7	-	-
Stock-Based Compensation	8.25	10.25	11.83	32.63	36.58
Provision & Write-off of Bad Debts	-0.52	0.88	-	-1	1
Other Operating Activities	-	-	0	8.15	-
Change in Accounts Receivable	16.35	-8.37	-7.82	-5.98	2.35
Change in Inventory	-1.64	-2.55	2.58	-3.66	-0.28
Change in Accounts Payable	-1.38	0.45	-4.73	-0.9	-7.11
Change in Other Net Operating Assets	-16.86	-7.38	-34.52	9.23	18.2
Operating Cash Flow	38.92	27.01	-15.83	20.65	0.77
Operating Cash Flow Growth	44.09%	-	-	2571.41%	-96.55%
Capital Expenditures	-0.06	-0.14	-	-	-0.05
Sale (Purchase) of Intangibles	-	-12.5	-7	-	-10
Investment in Securities	-20.38	-6.49	14.1	-10.88	43.45
Investing Cash Flow	-20.44	-19.13	7.1	-10.88	33.4
Long-Term Debt Issued	-	-	-	98.5	8.44
Long-Term Debt Repaid	-33.33	-	-	-100	-8.44
Net Debt Issued (Repaid)	-33.33	-	-	-1.5	-
Issuance of Common Stock	0.15	-	12.5	-	0.07
Other Financing Activities	-0.67	-	-0.28	-30.43	-10
Financing Cash Flow	-33.85	-	12.22	-31.93	-9.93
Net Cash Flow	-15.37	7.88	3.5	-22.16	24.24
Free Cash Flow	38.86	26.87	-15.83	20.65	0.73
Free Cash Flow Growth	44.64%	-	-	2740.44%	-96.71%
Free Cash Flow Margin	16.86%	11.40%	-6.94%	8.16%	0.32%
Free Cash Flow Per Share	0.79	0.56	-0.35	0.51	0.02
Cash Interest Paid	10.77	11.63	10.32	10.34	9.7
Cash Income Tax Paid	1.22	0.74	0.38	0.32	0.21
Levered Free Cash Flow	29.49	1.79	-1.34	8.08	-17.23
Unlevered Free Cash Flow	37.28	10.12	5.91	16.08	-8.45
Change in Net Working Capital	1.79	19.8	27.96	-3.97	-10.56

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q